Fate Therapeutics, Inc. (FATE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.48+2.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FATE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||
| Revenues | 6.5 | 6.6 | 13.6 | 63.5 | 96.3 | 55.8 | 31.4 | 10.7 | 4.7 | — | — | 2.4 | 1.0 | 1.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | 2.4 | 1.0 | 1.0 |
| Operating Expenses & Income | ||||||||||||||
| R&D Expenses | 100.4 | 107.8 | 135.0 | 172.6 | 320.5 | 215.5 | 125.6 | 87.8 | 56.0 | 34.4 | 26.5 | 19.9 | 16.4 | 12.0 |
| Operating Income | (133.6) | (147.7) | (210.3) | (190.5) | (308.4) | (217.0) | (128.1) | (100.7) | (67.1) | (42.1) | (32.0) | (27.8) | (24.9) | (17.7) |
| Earnings from Continuing Operations | ||||||||||||||
| Interest Expense | — | — | — | — | — | 0.0 | 0.0 | 1.8 | 1.7 | 1.3 | 1.6 | 2.2 | 0.5 | 0.8 |
| Interest & Investment Income | 8.2 | 11.1 | 17.3 | 17.2 | 5.8 | 1.3 | 2.4 | 4.3 | 2.2 | 0.6 | 0.1 | 0.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | (1.3) | (2.4) | (2.6) | (0.5) | 0.7 | 1.5 | 2.2 | 0.5 | 0.8 |
| Asset Writedown | — | — | 13.4 | 0.0 | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | 0.0 | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||
| Net Income | (126.0) | (136.3) | (186.3) | (160.9) | (281.7) | (212.2) | (173.4) | (98.1) | (66.6) | (43.0) | (33.5) | (30.0) | (25.9) | (20.9) |
| Per Share | ||||||||||||||
| Basic EPS | (1.05) | (1.15) | (1.64) | (1.64) | (2.91) | (2.24) | (2.10) | — | — | — | — | — | — | — |
| Diluted EPS | (1.05) | (1.15) | (1.64) | (1.64) | (2.91) | (2.24) | (2.10) | — | — | — | — | — | — | — |
| Revenue per Share | 0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 120.4 | 118.8 | 113.7 | 98.4 | 96.8 | 94.7 | 82.4 | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 120.4 | 118.8 | 113.7 | 98.4 | 96.8 | 94.7 | 82.4 | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||
| EBITDA | — | (134.8) | (191.3) | (172.2) | (294.6) | (211.1) | (125.0) | (98.5) | (65.9) | (41.2) | (31.1) | (27.1) | (24.4) | (17.1) |
| EBIT | (133.6) | (147.7) | (210.3) | (190.5) | (308.4) | (217.0) | (128.1) | (100.7) | (67.1) | (42.1) | (32.0) | (27.8) | (24.9) | (17.7) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.